Cerevel Therapeutics Holdings Future Growth

Future criteria checks 0/6

Cerevel Therapeutics Holdings is forecast to grow earnings and revenue by 16% and 70.8% per annum respectively while EPS is expected to grow by 20.4% per annum.

Key information

16.0%

Earnings growth rate

20.4%

EPS growth rate

Biotechs earnings growth	25.1%
Revenue growth rate	70.8%
Future return on equity	n/a
Analyst coverage	Good
Last updated	19 May 2024

Recent future growth updates

Recent updates

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Apr 30

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jan 02

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Jul 08

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Jul 14

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Jun 09

Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Jan 29

Cerevel Therapeutics (CERE) Investor Presentation - Slideshow

Nov 18

Cerevel Therapeutics reports Q3 results

Nov 16

Dosing underway in Cerevel Therapeutics' tavapadon trials for Parkinson’s disease

Oct 30

Earnings and Revenue Growth Forecasts

NasdaqCM:CERE - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	61	-578	-464	-453	5
12/31/2025	N/A	-559	-496	-534	7
12/31/2024	N/A	-523	-297	-436	9
3/31/2024	N/A	-460	-371	-367	N/A
12/31/2023	N/A	-433	-346	-342	N/A
9/30/2023	N/A	-393	-336	-332	N/A
6/30/2023	N/A	-397	-343	-340	N/A
3/31/2023	N/A	-388	-323	-320	N/A
12/31/2022	N/A	-352	-297	-293	N/A
9/30/2022	N/A	-318	-263	-258	N/A
6/30/2022	N/A	-280	-227	-222	N/A
3/31/2022	N/A	-243	-218	-210	N/A
12/31/2021	N/A	-225	-189	-179	N/A
9/30/2021	N/A	-196	-184	-168	N/A
6/30/2021	N/A	-173	-167	-144	N/A
3/31/2021	N/A	-146	-146	-125	N/A
12/31/2020	N/A	-148	-137	-118	N/A
9/30/2020	N/A	-175	-124	-112	N/A
6/30/2020	N/A	-172	-116	-111	N/A
3/31/2020	N/A	-151	-97	-94	N/A
12/31/2019	N/A	-128	-72	-71	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CERE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CERE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CERE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CERE is forecast to have no revenue next year.

High Growth Revenue: CERE is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CERE's Return on Equity is forecast to be high in 3 years time

Cerevel Therapeutics Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target increased by 9.7% to US$36.60

Price target decreased by 8.1% to US$34.13

Price target decreased by 7.4% to US$34.38

Price target decreased by 8.8% to US$35.20

Price target decreased by 9.3% to US$37.09

Price target increased to US$43.29

Recent updates

Executive Chairman notifies of intention to sell stock

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Price target increased by 9.7% to US$36.60

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

Independent Director notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Shareholder dilution

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $449.999991 million.

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $449.999991 million.

Executive Chairman notifies of intention to sell stock

President recently bought US$2.0m worth of stock

Price target decreased by 8.1% to US$34.13

Price target decreased by 7.4% to US$34.38

Executive Chairman notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. to Report Q2, 2023 Results on Aug 02, 2023

High number of new directors

Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer, Effective from June 20, 2023

Executive Chairman & CEO notifies of intention to sell stock

Cerevel Therapeutics Appoints Susan Altschuller as Chief Financial Officer

Executive Chairman & CEO notifies of intention to sell stock

Cerevel Therapeutics Holdings, Inc. Announces Executive Changes

Price target decreased by 8.8% to US$35.20

Executive Chairman & CEO notifies of intention to sell stock

Price target decreased by 9.3% to US$37.09

Executive Chairman & CEO notifies of intention to sell stock

Executive Chairman & CEO exercised options and sold US$1.5m worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Executive Chairman & CEO exercised options and sold US$1.3m worth of stock

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Executive Chairman & CEO exercised options and sold US$1.2m worth of stock

Chief Scientific Officer exercised options and sold US$561k worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Scientific Officer exercised options and sold US$561k worth of stock

Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Price target increased to US$43.29

President exercised options and sold US$371k worth of stock

President exercised options and sold US$186k worth of stock

Cerevel Therapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $253.75 million.

Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering

President notifies of intention to sell stock

Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13

Cerevel Therapeutics Holdings, Inc. to Report Q2, 2022 Results on Aug 01, 2022

Chief Scientific Officer exercised options and sold US$663k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Price target decreased to US$39.71

Cerevel Therapeutics Appoints Suneet Varma to Serve as Member of Its Board of Directors

Chief Scientific Officer exercised options and sold US$1.4m worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q1, 2022 Results on May 10, 2022

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$1.2m worth of stock

Chief Scientific Officer exercised options and sold US$895k worth of stock

Chief Scientific Officer exercised options and sold US$663k worth of stock

Cerevel Therapeutics Holdings, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety

Chief Scientific Officer exercised options and sold US$663k worth of stock

Chief Scientific Officer notifies of intention to sell stock

Chief Scientific Officer notifies of intention to sell stock

Price target increased to US$46.33

Price target decreased to US$32.67

Price target increased to US$36.33

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Cerevel Therapeutics Holdings, Inc. Announces Positive Topline Results for Cvl-231 in Phase 1B Clinical Trial in Patients with Schizophrenia

Cerevel Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to CVL-871 for the Treatment of Dementia-Related Apathy

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate